Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.

Abstract

T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.

• Authors: Yuan-Hong Huang, Chao-Ling Wan, Hai-Ping Dai, Sheng-Li Xue
• Journal: Annals of hematology (Ann Hematol) Vol. 102 Issue 8 Pg. 2001-2013 (Aug 2023) ISSN: 1432-0584 [Electronic] Germany
• PMID: 37227492 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Topics

• Humans
• Immunotherapy
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy)
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (therapy)
• Lymphoma (therapy)
• T-Lymphocytes
• Molecular Targeted Therapy